Stock listing
NASDAQ:KPRX Kiora Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Kiora Pharmaceuticals, Inc.
Follow Kiora Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:KPRX
$0.72 USD -0.10 (-12.7%)
Close on Nov 20, 2026
- Day range
- $0.72 – $0.816 USDNov 20, 2026
- Volume
- 64,687 sharesNov 20, 2026
- Market cap
- $3.19M USDAt the close on Nov 20, 2026 · price × 4.42M shares outstanding
- 52-week range
- $0.72 – $2.91 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $62,264 USDMedian day 18,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KPRX · Home | $0.72 USD | -0.105 (-12.7%) | 64,687 | $0.816 | $0.816 | $0.72 | $0.825 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KPRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.72 | -0.105 | -12.7% | $0.816 | $0.816 | $0.72 | 64,687 | |
| $0.825 | -0.105 | -11.3% | $0.93 | $0.95 | $0.791 | 118,769 | |
| $0.93 | -0.052 | -5.3% | $0.96 | $0.981 | $0.926 | 65,953 | |
| $0.982 | -0.248 | -20.2% | $1.25 | $1.25 | $0.953 | 76,034 | |
| $1.23 | -0.10 | -7.5% | $1.36 | $1.39 | $1.20 | 88,962 | |
| $1.33 | -0.02 | -1.5% | $1.33 | $1.39 | $1.33 | 20,640 | |
| $1.35 | -0.03 | -2.2% | $1.42 | $1.491 | $1.33 | 20,500 | |
| $1.38 | -0.13 | -8.6% | $1.51 | $1.51 | $1.37 | 22,800 | |
| $1.51 | +0.07 | +4.9% | $1.47 | $1.56 | $1.41 | 41,800 | |
| $1.44 | -0.06 | -4.0% | $1.49 | $1.51 | $1.40 | 54,300 | |
| $1.50 | -0.16 | -9.6% | $1.68 | $1.68 | $1.48 | 52,100 | |
| $1.66 | -0.07 | -4.0% | $1.71 | $1.74 | $1.64 | 11,200 | |
| $1.73 | +0.10 | +6.1% | $1.72 | $1.83 | $1.62 | 40,500 | |
| $1.63 | +0.07 | +4.5% | $1.65 | $1.85 | $1.61 | 270,900 | |
| $1.56 | -0.20 | -11.4% | $1.78 | $1.825 | $1.55 | 100,700 | |
| $1.76 | -0.60 | -25.4% | $2.21 | $2.22 | $1.73 | 488,700 | |
| $2.36 | +0.06 | +2.6% | $2.32 | $2.57 | $2.32 | 29,900 | |
| $2.30 | +0.09 | +4.1% | $2.20 | $2.31 | $2.20 | 16,500 | |
| $2.21 | -0.08 | -3.5% | $2.28 | $2.28 | $2.21 | 25,000 | |
| $2.29 | -0.03 | -1.3% | $2.32 | $2.37 | $2.24 | 24,400 | |
| $2.32 | -0.02 | -0.9% | $2.36 | $2.36 | $2.32 | 900 | |
| $2.34 | +0.01 | +0.4% | $2.35 | $2.37 | $2.32 | 30,100 | |
| $2.33 | -0.05 | -2.1% | $2.38 | $2.41 | $2.32 | 23,500 | |
| $2.38 | -0.02 | -0.8% | $2.37 | $2.38 | $2.36 | 3,400 | |
| $2.40 | -0.01 | -0.4% | $2.42 | $2.42 | $2.36 | 11,900 | |
| $2.41 | -0.06 | -2.4% | $2.46 | $2.46 | $2.35 | 25,400 | |
| $2.47 | 0.00 | 0.0% | $2.47 | $2.49 | $2.45 | 18,300 | |
| $2.47 | -0.09 | -3.5% | $2.55 | $2.55 | $2.47 | 3,000 | |
| $2.56 | +0.02 | +0.8% | $2.53 | $2.56 | $2.52 | 12,800 | |
| $2.54 | +0.01 | +0.4% | $2.515 | $2.57 | $2.515 | 4,500 | |
| $2.53 | 0.00 | 0.0% | $2.52 | $2.54 | $2.48 | 24,300 | |
| $2.53 | +0.03 | +1.2% | $2.51 | $2.54 | $2.49 | 21,000 | |
| $2.50 | -0.03 | -1.2% | $2.52 | $2.62 | $2.50 | 20,200 | |
| $2.53 | -0.03 | -1.2% | $2.56 | $2.57 | $2.52 | 8,600 | |
| $2.56 | -0.02 | -0.8% | $2.55 | $2.56 | $2.55 | 3,400 | |
| $2.58 | +0.02 | +0.8% | $2.57 | $2.58 | $2.56 | 16,800 | |
| $2.56 | -0.04 | -1.5% | $2.57 | $2.57 | $2.56 | 2,400 | |
| $2.60 | -0.07 | -2.6% | $2.63 | $2.64 | $2.58 | 6,700 | |
| $2.67 | +0.04 | +1.5% | $2.619 | $2.67 | $2.619 | 6,700 | |
| $2.63 | -0.04 | -1.5% | $2.623 | $2.63 | $2.60 | 2,400 | |
| $2.67 | +0.05 | +1.9% | $2.63 | $2.67 | $2.58 | 19,400 | |
| $2.62 | -0.09 | -3.3% | $2.73 | $2.75 | $2.62 | 10,100 | |
| $2.71 | +0.03 | +1.1% | $2.70 | $2.80 | $2.63 | 7,600 | |
| $2.68 | -0.08 | -2.9% | $2.75 | $2.75 | $2.62 | 6,200 | |
| $2.76 | +0.09 | +3.4% | $2.63 | $2.85 | $2.63 | 49,300 | |
| $2.67 | +0.07 | +2.7% | $2.65 | $2.70 | $2.63 | 20,000 | |
| $2.60 | 0.00 | 0.0% | $2.60 | $2.63 | $2.57 | 28,500 | |
| $2.60 | -0.05 | -1.9% | $2.66 | $2.66 | $2.59 | 19,600 | |
| $2.65 | 0.00 | 0.0% | $2.70 | $2.70 | $2.601 | 19,000 | |
| $2.65 | +0.07 | +2.7% | $2.59 | $2.65 | $2.59 | 10,500 | |
| $2.58 | +0.09 | +3.6% | $2.48 | $2.58 | $2.47 | 15,900 | |
| $2.49 | -0.02 | -0.8% | $2.51 | $2.60 | $2.49 | 15,800 | |
| $2.51 | -0.04 | -1.6% | $2.64 | $2.64 | $2.49 | 9,500 | |
| $2.55 | 0.00 | 0.0% | $2.58 | $2.625 | $2.54 | 4,500 | |
| $2.55 | -0.04 | -1.5% | $2.63 | $2.66 | $2.55 | 3,000 | |
| $2.59 | +0.08 | +3.2% | $2.53 | $2.64 | $2.53 | 10,300 | |
| $2.51 | 0.00 | 0.0% | $2.54 | $2.56 | $2.50 | 14,500 | |
| $2.51 | -0.11 | -4.2% | $2.52 | $2.555 | $2.50 | 14,100 | |
| $2.62 | -0.04 | -1.5% | $2.67 | $2.67 | $2.62 | 2,500 | |
| $2.66 | +0.07 | +2.7% | $2.58 | $2.72 | $2.58 | 8,700 | |
| $2.59 | 0.00 | 0.0% | $2.58 | $2.592 | $2.53 | 20,400 | |
| $2.59 | -0.16 | -5.8% | $2.74 | $2.75 | $2.59 | 25,244 | |
| $2.75 | +0.09 | +3.4% | $2.65 | $2.75 | $2.65 | 11,049 | |
| $2.66 | +0.04 | +1.5% | $2.61 | $2.66 | $2.532 | 15,800 | |
| $2.62 | +0.02 | +0.8% | $2.54 | $2.63 | $2.54 | 9,600 |
Splits
3 splits since 2019 · NASDAQ:KPRX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-9 | Consolidation | |
| 1-for-40 | Consolidation | |
| 1-for-15 | Consolidation |
- Ticker
- NASDAQ:KPRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
How KIO-401 Positions Kiora as a Late-Stage Retinal Therapeutics Company
Latest deck · Oct 29, 2026
Investor Presentation (October 2026)
Investor deck · 29 slides
Latest news
How KIO-401 Positions Kiora as a Late-Stage Retinal Therapeutics Company
Nov 19, 2026
Closed $0.72 (-12.7%) on Nov 20, 2026
Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 12, 2026
Closed $1.33 (-1.5%) on Nov 12, 2026
Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan
Oct 29, 2026
Closed $1.76 (-25.4%) on Oct 29, 2026
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Sep 8, 2026
Closed $2.51 (-1.6%) on Sep 8, 2026
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Aug 19, 2026
Closed $2.60 (+0.4%) on Aug 19, 2026
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 7, 2026
Closed $2.64 (+3.1%) on Aug 7, 2026
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Jul 2, 2026
Closed $2.63 (-1.1%) on Jul 2, 2026
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Jun 18, 2026
Closed $2.53 (-1.6%) on Jun 18, 2026
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
Closed $2.45 (0.0%) on May 8, 2026
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Apr 14, 2026
Closed $2.44 (0.0%) on Apr 14, 2026
Kiora Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 83 in all · newest Nov 19, 2026 · oldest 2021
- Decks
- 40 decks · latest Oct 29, 2026
Where Kiora Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KPRX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:KPRX | BOATS | United States | USD |
| Lang & Schwarz:A40EG5 | Lang & Schwarz | Germany | EUR |
| Munich:7EY | Munich | Germany | EUR |
| Frankfurt:7EY | Frankfurt | Germany | EUR |
| gettex:7EY | gettex | Germany | EUR |
Valuation
EV/sales −12.8× against a median of −0.8×: 2nd lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$12.81M USD
- P/E
- Loss
- EV/sales
- −12.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.2×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.54
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX | US$3.19M | −US$12.81M | n/a | −12.8× | n/a | 0.2× | n/a | 0.0× | 1.54 |
| Liminatus Pharma, Inc. · NASDAQ:LIMN | US$3.37M | US$1.80M | n/a | n/a | n/a | 11.2× | n/a | 4.8× | 0.94 |
| Xenetic Biosciences, Inc. · NASDAQ:XBIO | US$3.28M | −US$2.53M | n/a | −0.8× | n/a | 0.7× | −123.7% | 0.0× | 1.46 |
| Aprea Therapeutics, Inc. · NASDAQ:APRE | US$3.25M | −US$34.60M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.73 |
| Spago Nanomedical AB · OMXSTO:SPAGO | US$3.20M | US$22,063 | n/a | 5.6× | n/a | 1.0× | n/a | 0.0× | n/a |
| Azitra Inc · AMEX:AZTR | US$3.13M | −US$618,677 | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.60 |
| NuCana plc · NASDAQ:NCNA | US$3.12M | −US$21.37M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.58 |
| Revive Therapeutics Ltd. · CSE:RVV | US$3.10M | US$3.14M | n/a | n/a | n/a | n/a | n/a | n/a | 0.56 |
| Skye Bioscience, Inc. · NASDAQ:SKYE | US$3.10M | −US$1.71M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 0.85 |
| Creative Medical Technology Holdings, Inc. · NASDAQ:CELZ | US$3.06M | −US$3.79M | n/a | −1,263× | n/a | 0.4× | n/a | 0.0× | 1.53 |
| Oncology Pharma Inc. · OTC:ONPH | US$3.04M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.62 |
| Median of the others | US$3.13M | −US$1.71M | −0.8× | 0.7× | −123.7% | 0.0× | 0.94 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.14 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Brian M. Strem | President & Chief Executive Officer |
| Melissa Tosca | Chief Financial Officer |
| Keith J. Lane | Executive Vice President of Clinical Development and Regulatory Affairs |
| Stefan Sperl | Executive Vice President of CMC and Operations |
Board
| Director | Role |
|---|---|
| Praveen Tyle | Chairman |
| Aron Shapiro | Director |
| Brian M. Strem | President & Chief Executive Officer |
| Carmine Stengone | Director |
| David Hollander | Director |
| Erin Parsons | Director |
| Lisa Walters-Hoffert | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −1.5% |
| Q2 2026 | Aug 7, 2026 | +0.8% |
| Q1 2026 | May 8, 2026 · Before open | 0.0% |
| Q4 2025 | Mar 25, 2026 | −4.4% |
| Q3 2025 | Nov 7, 2025 · Before open | +0.4% |
| Q2 2025 | Aug 8, 2025 · Before open | −1.3% |
| Q1 2025 | May 9, 2025 · Before open | +4.2% |
| Q4 2024 | Mar 24, 2025 · Before open | −2.7% |
| Q3 2024 | Nov 8, 2024 · Before open | −1.2% |
| Q2 2024 | Aug 9, 2024 · Before open | +2.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · Before open | +0.2% |
| Q4 2023 | Mar 25, 2024 · Before open | −3.2% |
| Q3 2023 | Nov 9, 2023 · Before open | +3.2% |
| Q2 2023 | Aug 8, 2023 · Before open | −1.6% |
| Q1 2023 | May 9, 2023 · Before open | 0.0% |
| Q4 2022 | Mar 23, 2023 · Before open | −9.4% |
| Q3 2022 | Nov 9, 2022 · Before open | −5.8% |
| Q2 2022 | Aug 12, 2022 · Before open | −10.4% |
| Q1 2022 | Apr 15, 2022 · Before open | −5.9% |
| Q4 2021 | Mar 2, 2022 | −5.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 29 slides | Oct 29, 2026 |
| Investor Presentation (October 2026) | Investor deck | 29 slides | Oct 29, 2026 |
| Investor Presentation (2026) | Investor deck | 24 slides | 2026 |
| H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (August 2025) | Conference | 25 slides | Aug 13, 2025 |
| Investor Presentation (October 2024) | Investor deck | 41 slides | Oct 29, 2024 |
| Investor Presentation (February 2024) | Investor deck | 43 slides | Feb 12, 2024 |
| Merger or Acquisition (January 2024) | Merger or acquisition | 19 slides | Jan 31, 2024 |
| Investor Presentation (November 2023) | Investor deck | 38 slides | Nov 9, 2023 |
| IPO Roadshow (May 2023) | IPO roadshow | 47 slides | May 15, 2023 |
| Investor Presentation (January 2023) | Investor deck | 28 slides | Jan 9, 2023 |
All 40 decks
IPO
Went public as EYEGATE PHARMACEUTICALS INC. Priced at US$6.00 a share. Final prospectus filed on Feb 13, 2015.
- Price
- US$6.00 a share
- Shares offered
- 683,250 shares of common stock
- Offering size
- US$4.1 million
- Underwriters' option
- Up to 102,487 more shares
- Underwriters
- Aegis Capital Corp, Chardan Capital Markets, LLC · In the order on the cover
- Shares delivered
- On or about Feb 19, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 14, 2014 |
| Filed publicly | Jul 30, 2014 |
| Amended 9 times | Newest Feb 4, 2015 |
| Shares registered with an exchange | Sep 30, 2014 |
| Declared effective by the SEC | Feb 12, 2015 |
| Final prospectus, with the price | Feb 13, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 13, 2015 |
| EFFECT · Notice that a registration is effective | Feb 12, 2015 |
| CORRESP · Letter to the SEC | Feb 10, 2015 |
| CORRESP · Letter to the SEC | Feb 10, 2015 |
| 8-A12G · Registration of a class of shares | Feb 5, 2015 |
| S-1/A · Registration statement, amended | Feb 4, 2015 |
| S-1/A · Registration statement, amended | Jan 26, 2015 |
| CORRESP · Letter to the SEC | Jan 23, 2015 |
| CORRESP · Letter to the SEC | Jan 23, 2015 |
| FWP · Free writing prospectus | Jan 16, 2015 |
All 42 filings
Open IPO · From the cover of the final prospectus (424B4) filed Feb 13, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 16.0M | 0 | 0 | 0 | 12.1K | 2.69M | 1.65M | 407.5K | 669.3K |
| Cost of revenue | 24.8K | 379.5K | 4.03M | 134.0K | 227.3K | 3.27M | 4.89K | 8.06M | 10.3M | 8.42M |
| Gross profit | -24.8K | 16.0M | -4.03M | -134.0K | -227.3K | -3.26M | 2.68M | -6.40M | -9.92M | -7.75M |
| Research and development | 10.8M | 7.84M | 4.03M | 3.45M | 5.35M | 3.57M | 5.39M | 8.06M | 10.3M | 8.42M |
| Selling, general and administrative | 5.75M | 5.54M | 4.66M | 8.28M | 5.32M | 4.24M | 4.41M | 4.44M | 4.64M | 5.59M |
| Operating income | -12.8M | 4.51M | -12.6M | -12.3M | -14.2M | -6.87M | -7.00M | -10.8M | -14.6M | -13.3M |
| Depreciation and amortization | 24.8K | 19.2K | 51.8K | 41.6K | 45.3K | 33.4K | 51.7K | 38.5K | 19.3K | 5.18K |
| EBITDA | -12.8M | 4.53M | -12.5M | -12.3M | -14.2M | -6.84M | -6.95M | -10.8M | -14.5M | -13.3M |
| Interest expense | 20.0K | 21.4K | 11.1K | 8.60K | 6.85K | 4.19K | 325 | 1.04K | 1.22K | 275 |
| Income before tax | -12.1M | 5.66M | -12.4M | -13.7M | -14.0M | -6.85M | -7.00M | -10.7M | -14.6M | -13.3M |
| Income tax | -1.28M | 2.07M | 90.3K | -113.0K | -192.6K | 12.1K | 95.4K | 86.0K | -1.34M | 0 |
| Net income | -10.8M | 3.59M | -12.5M | -13.6M | -13.8M | -6.86M | -7.10M | -10.8M | -13.2M | -13.3M |
| Earnings per share, basic | -2.60 | 0.93 | -24.25 | -18.55 | -57.12 | -1.49 | -2.23 | -4.57 | -0.93 | -1.51 |
| Earnings per share, diluted | -2.64 | 0.87 | -24.25 | -18.55 | -57.12 | -1.49 | -2.23 | -4.57 | -0.93 | -1.51 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.70M | 3.79M | 2.45M | 5.96M | 7.85M | 1.19M | 3.78M | 8.00M | 7.81M | 3.64M |
| Short-term investments | 8.39M | 23.0M | 0 | |||||||
| Receivables | 1.52M | 601.2K | 0 | 1.37M | 529.6K | 91.0K | 4.86K | 18.4K | 23.7K | 53.8K |
| Inventory | 1 | |||||||||
| Current assets | 21.7M | 29.7M | 4.74M | 7.68M | 8.99M | 1.73M | 4.32M | 8.48M | 8.46M | 4.15M |
| Property, plant and equipment | 91.7K | 5.23K | 8.06K | 55.2K | 74.0K | 30.6K | 16.8K | 43.5K | 55.8K | 38.0K |
| Goodwill | 0 | 0 | 3.63M | 1.53M | 1.53M | 1.53M | 5.44M | |||
| Total assets | 24.3M | 36.5M | 13.7M | 18.7M | 20.1M | 15.3M | 10.1M | 14.3M | 14.3M | 9.73M |
| Accounts payable | 1.06M | 415.6K | 206.3K | 1.01M | 160.6K | 434.8K | 210.3K | 63.7K | 706.1K | 1.41M |
| Current liabilities | 3.63M | 6.01M | 1.63M | 3.27M | 1.61M | 1.98M | 1.41M | 3.86M | 14.8M | 7.31M |
| Long-term debt | 278.2K | 0 | ||||||||
| Total debt | 368.3K | 57.2K | 106.9K | 105.8K | 209.4K | 278.2K | 0 | 4.71K | 16.1K | 28.7K |
| Total liabilities | 8.13M | 10.7M | 7.60M | 7.27M | 5.55M | 5.57M | 3.49M | 5.34M | 16.2M | 10.1M |
| Shareholders' equity | 16.1M | 25.8M | 6.11M | 11.4M | 14.6M | 9.73M | 6.62M | 8.94M | -1.93M | -329.4K |
| Shares outstanding | 3.76M | 3.00M | 856.2K | 1.80M | 316.6K | 5.56M | 4.08M | 3.04M | 17.3M | 10.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.96M | 8.56M | -9.56M | -10.4M | -10.7M | -7.32M | -8.15M | -10.8M | -6.47M | -8.41M |
| Capital spending | -110.8K | -6.26K | 0 | 0 | -63.9K | -20.1K | 0 | -20.0K | -37.0K | 0 |
| Free cash flow | -10.1M | 8.55M | -9.56M | -10.4M | -10.7M | -7.34M | -8.15M | -10.9M | -6.51M | -8.41M |
| Cash from investing | 14.4M | -22.7M | 0 | 6.38K | -157.0K | -244.4K | 0 | -270.0K | -37.0K | 174.7K |
| Cash from financing | 265.7K | 15.5M | 5.97M | 8.62M | 17.6M | 5.00M | 3.92M | 11.3M | 10.7M | 3.50M |
| Dividends paid | -7.33K | |||||||||
| Share buybacks | 0 | -15.6K | 0 | -2.61K | 2.91M | |||||
| Change in cash | 4.90M | 1.34M | -3.55M | -1.89M | 6.67M | -2.59M | -4.23M | 198.2K | 4.17M | -4.73M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Material contract | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 8, 2026 | Management or board change | SEC |
| 8-K · Current report | Aug 19, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Management or board change | SEC |
| 424B3 · Prospectus | May 28, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 26, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 20, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 20, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 18, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 8, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | May 1, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| D | Apr 21, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 7, 2026 | Material contract | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 2, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 25, 2026 | Results | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 7, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Sep 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 17, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 16, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 15, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 12, 2025 | Current report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | Jul 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 20, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 10, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 4, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 3, 2025 | Material contract | SEC |
| 8-K · Current report | May 9, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 15, 2025 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | May 29, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | May 29, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | May 10, 2024 | Offer document | SEC |
| 8-K · Current report | May 2, 2024 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Mar 29, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Mar 28, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 26, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Mar 25, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 25, 2024 | Results | SEC |
| 10-K · Annual report | Mar 25, 2024 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 15, 2024 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Mar 4, 2024 | Other filings | SEC |
| S-3 · Registration statement | Feb 28, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| D | Feb 14, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 1, 2024 | Material contract | SEC |
| 8-K · Current report | Jan 31, 2024 | Material contract | SEC |
| 8-K · Current report | Jan 16, 2024 | Current report | SEC |
| 8-K · Current report | Nov 9, 2023 | Current report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2023 | Current report | SEC |
| S-8 · Registration statement for employee plans | Oct 13, 2023 | Offer document | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 27, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Sep 21, 2023 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Sep 1, 2023 | Meeting notice | SEC |
| 8-K · Current report | Sep 1, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 10, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 8, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2023 | Management or board change | SEC |
| DEF 14A · Proxy statement | Jul 21, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jul 20, 2023 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jul 11, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jun 21, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Jun 15, 2023 | Material contract | SEC |
| SC 13G · Big-stake notice | Jun 13, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jun 6, 2023 | Material contract | SEC |
| 424B1 · Prospectus | Jun 2, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 2, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 31, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 31, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 31, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 24, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 24, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 23, 2023 | Other filings | SEC |
| FWP · Free writing prospectus | May 15, 2023 | Offer document | SEC |
| S-1/A · Registration statement, amended | May 12, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 9, 2023 | Other filings | SEC |
| 8-K · Current report | May 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2023 | Quarterly report | SEC |
| S-1 · Registration statement | May 5, 2023 | Offer document | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 27, 2023 | Current report | SEC |
| 8-K · Current report | Mar 30, 2023 | Current report | SEC |
| 8-K · Current report | Mar 23, 2023 | Results | SEC |
| 10-K · Annual report | Mar 23, 2023 | Annual report | SEC |
| 4 · Change in ownership | Mar 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2023 | Insider trade | SEC |
This page holds 200 of 929 filings. Open Filings
Cap table
Built by 6ix from Kiora Pharmaceuticals, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 4,424,387
- Fully diluted
- 4,424,387
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 4,424,387 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 4,424,387 |
| Sep 30, 2026 | 4,424,387 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Peter Greenleaf Other companies: Pelthos Therapeutics Inc. (Director · Since at least Jul 1, 2025); Aurinia Pharmaceuticals Inc (Chief Executive Officer, Director · Since at least Jan 1, 2021); Antares Pharma Inc (Director · Dec 12, 2018 – May 24, 2022 · Past); BioDelivery Sciences International Inc (Director · May 21, 2018 – Mar 22, 2022 · Past); Avalo Therapeutics, Inc. (Director · Mar 27, 2018 – Aug 7, 2019 · Past); Sucampo Pharmaceuticals Inc (Chief Executive Officer · Sep 30, 2017 – Feb 13, 2018 · Past) | Director · Jul 10, 2018 – Feb 1, 2019 · Past |
| Steven Boyd Other companies: Tenax Therapeutics, Inc. (Director · Aug 19, 2020 – May 18, 2022 · Past); Tetraphase Pharmaceuticals Inc (Director · Jan 22, 2020 – Jul 28, 2020 · Past); Vaxart, Inc. (Director · Nov 5, 2019 – Jun 26, 2020 · Past); Aytu BioPharma, Inc. (Director · Apr 18, 2019 – Mar 20, 2021 · Past); Del Frisco's Restaurant Group Inc (Director · Nov 30, 2018 – Nov 30, 2018 · Past); Avalo Therapeutics, Inc. (Director · May 19, 2017 – Mar 10, 2022 · Past) | Director · May 14, 2018 – Jul 27, 2021 · Past |
| Paul G Chaney Other companies: Sesen Bio Inc (Director · Jun 12, 2018 – Jun 12, 2018 · Past); Eleven Biotherapeutics Inc (Director · Feb 27, 2014 – May 19, 2017 · Past); Osi Pharmaceuticals Inc (Exec. VP & Pres. (OSI) Eyetech · May 1, 2006 – May 1, 2006 · Past) | Director · Feb 12, 2015 – Mar 3, 2023 · Past |
| Kenneth L Gayron Other companies: Research Solutions, Inc (Director · Since at least Dec 4, 2023); Avid Technology Inc (EVP, CFO & Corp Treasurer · Jun 15, 2022 – Nov 7, 2023 · Past) | Director · Mar 3, 2023 – Sep 29, 2023 · Past |
| Lisa Walters-Hoffert Other companies: Flux Power Holdings, Inc. (Director · Since at least Jun 28, 2019); Dare Bioscience, Inc. (Chief Financial Officer · Jul 19, 2017 – Jan 24, 2023 · Past) | Director · Since at least Jul 1, 2024 |
| Praveen Tyle Other companies: Skye Bioscience, Inc. (Director · Jul 22, 2021 – Feb 29, 2024 · Past); Lexicon Pharmaceuticals, Inc. (EVP, R&D · Feb 11, 2021 – Feb 28, 2021 · Past) | Director · Since at least Feb 1, 2021 |
| Eric J. Daniels Other companies: Plus Therapeutics, Inc. (Chief Development Officer · Since at least Apr 9, 2026) | Chief Development Officer · Since at least Oct 21, 2021 |
| Erin Parsons Other companies: Alimera Sciences Inc (Director · Jan 4, 2023 – Sep 16, 2024 · Past) | Director · Since at least Mar 3, 2023 |
| Aron Shapiro | Director · Since at least Sep 29, 2023 |
| Bernard Malfroy-Camine | Director · Jul 10, 2018 – Feb 1, 2021 · Past |
All 20 people
| Person | Seat |
|---|---|
| Brian M. Strem | President & Chief Executive Officer · Since at least Jul 26, 2021 |
| Carmine Stengone | Director · Since at least Nov 5, 2026 |
| David Hollander | Director · Since at least Nov 5, 2026 |
| Keith J. Lane | Executive Vice President of Clinical Development and Regulatory Affairs · Since at least Sep 8, 2026 |
| Lisa Walters-Hoffert | Director · Since at least Nov 5, 2026 |
| Melissa Tosca | Chief Financial Officer · Since at least Sep 13, 2022 |
| Michael P Manzo | VP of Engineering · Feb 28, 2018 – Aug 3, 2021 · Past |
| Morton Goldberg | Director · Aug 28, 2015 – Feb 1, 2021 · Past |
| Ryan Randall Brenneman | Chief Financial Officer · Apr 25, 2016 – Jul 18, 2016 · Past |
| Stefan Sperl | Executive Vice President of CMC and Operations · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Kiora Pharmaceuticals, Inc.